Sadanjana Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.50 M
as on 23-10-2024
- Company Age 14 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.15 Cr
as on 23-10-2024
- Revenue -14.29%
(FY 2023)
- Profit 47.58%
(FY 2023)
- Ebitda -63.30%
(FY 2023)
- Net Worth 68.44%
(FY 2023)
- Total Assets 49.02%
(FY 2023)
About Sadanjana Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company has closed loans amounting to ₹1.15 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pathapati Raju and Venugopala Dandu serve as directors at the Company.
- CIN/LLPIN
U24233TG2010PTC069709
- Company No.
069709
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sadanjana Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pathapati Raju  | Director | 28-Jul-2010 | Current |
| Venugopala Dandu | Director | 28-Jul-2010 | Current |
Financial Performance of Sadanjana Pharma.
Sadanjana Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.29% decrease. The company also saw a substantial improvement in profitability, with a 47.58% increase in profit. The company's net worth Soared by an impressive increase of 68.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sadanjana Pharma?
In 2023, Sadanjana Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Radison Labs Private LimitedActive 18 years 1 monthPathapati Raju and Venugopala Dandu are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Punjab National Bank Creation Date: 19 Sep 2014 | ₹1.45 M | Satisfied |
Axis Bank Limited Creation Date: 13 Nov 2013 | ₹1.00 Cr | Satisfied |
How Many Employees Work at Sadanjana Pharma?
Sadanjana Pharma has a workforce of 1 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sadanjana Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sadanjana Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
